
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
By Richard M. Berlin, MD
about 18 years ago
Theoretical Models of Health Behaviorabout 18 years ago
The Differential Diagnosis of Childhood Developmental Disordersabout 18 years ago
Wrong Choicesabout 18 years ago
Coping With Obscene Phone Callsabout 18 years ago
Cyber Bullyingabout 18 years ago
The Dementias: Neuropsychiatric Syndromes of the 21st Centuryabout 18 years ago
Acupuncture: An Updateabout 18 years ago
Antipsychotics in Dementia: Evidence of Risk Mountsabout 18 years ago
Advances in Neuroimaging: Impact on Psychiatric Practice



